Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of daratumumab plus bortezomib and dexamethasone in relapsed multiple myeloma (1 prior line)
KCT0004352Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in multiple myeloma (MM), sponsored by Samsung Medical Center. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0004352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004352.